| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5990100 | TARO | Composition and method for treatment of psoriasis |
Mar, 2018
(6 years ago) | |
| US8715624 | TARO | Stable liquid desoximethasone compositions with reduced oxidized impurity |
May, 2026
(2 years from now) | |
| US8277780 | TARO | Stable liquid desoximethasone compositions with reduced oxidized impurity |
Sep, 2028
(4 years from now) | |
Topicort is owned by Taro.
Topicort contains Desoximetasone.
Topicort has a total of 3 drug patents out of which 1 drug patent has expired.
Expired drug patents of Topicort are:
- US5990100
Topicort was authorised for market use on 11 April, 2013.
Topicort is available in spray;topical dosage forms.
Topicort can be used as treatment of plaque psoriasis in patients 18 years of age or older.
The generics of Topicort are possible to be released after 01 September, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosage Form(NDF) | Apr 11, 2016 |
Drugs and Companies using
DESOXIMETASONE ingredient
Market Authorisation Date:
11 April, 2013Treatment:
Treatment of plaque psoriasis in patients 18 years of age or olderDosage:
SPRAY;TOPICAL
How can I launch a generic of TOPICORT before its drug patent expiration?
More Information on Dosage
TOPICORT family patents
